Brexanolone - Lipocine
Alternative Names: LPCN-1154; LPCN-1154ALatest Information Update: 03 Mar 2026
At a glance
- Originator Lipocine
- Class Antidepressants; Antiepileptic drugs; Small molecules; Steroids
- Mechanism of Action GABA A receptor modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Postnatal depression
Highest Development Phases
- Phase III Postnatal depression
Most Recent Events
- 17 Feb 2026 Lipocine completes a phase III trial in Postnatal depression (In adolescents, In adults) in USA (PO, Tablet) (NCT06979544)
- 20 Jan 2026 Lipocine completes enrolment in its phase-III trial in Postnatal depression in USA (In adolescents, In adults) (PO) (NCT06979544)
- 12 Jan 2026 Updated adverse events data from a phase III trial in Postnatal depression released by Lipocine